Table 2.
Difference in Peak E2 associated with patient characteristics
| Patient Characteristic | Difference in Peak E2 (95% CI) | P-value |
|---|---|---|
|
| ||
| FSH Dose | ||
| Low Dose | (reference) | |
| Medium Dose | 27.4 (−62.6, 117.4) | 0.55 |
| High Dose | 153.1 (60.7, 245.5) | <0.01 |
|
| ||
| Diagnosis | ||
| Ovulatory Controls | (reference) | |
| Polycystic Ovary Sundrome | −175.5 (−308.2, −42.9) | 0.01 |
|
| ||
| Age (per year) | −3.3 (−10.5, 3.9) | 0.37 |
|
| ||
| Body Mass Index (per point) | 10.5 (2.0, 19.1) | 0.02 |
|
| ||
| Total Testosteronea (per ng/mL) | 4.4 (−0.6, 9.4) | 0.08 |
|
| ||
| Antimüllerian Hormonea (per ng/mL) | 0.3 (−6.3, 6.9) | 0.93 |
|
| ||
| Estradiola (per pg/mL) | 1.6 (0.6, 2.6) | <0.01 |
Pooled analysis (n=30) of the difference in Peak E2 associated with patient variables as determined by linear mixed effects modeling with random intercept structure while adjusting for age, body mass index, total testosterone concentration, and antimüllerian hormone level.
a
Baseline levels. Bold text indicates a statistically significant difference with a p-value < 0.05.